WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

28.06.2016: WILEX AG: European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin ...More

 

 

 

Seite gelesen: 497147 | Heute: 218